



ADDRESS: COMMISSIONER FOR PATENTS AND TRADEMARKS  
Washington, D.C. 20231

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NO./TITLE
--------------------	---------------------	-----------------------	---------------------------

09/211,297 12/14/98 BOYLE

W A-451-F

0262/0223

U S PATENT OPERATION/RBW  
DEPT 430 M/S 27-4-A  
AMGEN  
ONE AMGEN CENTER DRIVE  
THOUSAND OAK CA 91320-1799

NOT ASSIGNED

1652  
DATE MAILED:

02/23/99

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS  
CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821 - 1.825 for the following reason(s):

1. This application fails to comply with the requirements of 37 CFR 1.821 - 1.825.
2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 CFR 1.821(c).
3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e).
4. A copy of the "Sequence Listing" in computer readable form has been submitted. The content of the computer readable form, however, does not comply with the requirements of 37 CFR 1.822 and/or 1.832, as indicated on the attached marked-up copy of the "Raw Sequence Listing."
5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR 1.825(d).
6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 CFR 1.821(e).
7. OTHER:


**APPLICANT MUST PROVIDE:**

- An initial or substitute computer readable form (CRF) copy of the "Sequence Listing."
- An initial or substitute paper copy of the "Sequence Listing," as well as an amendment directing its entry into the specification.
- A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b) or 1.825(d).

**FOR QUESTIONS REGARDING COMPLIANCE WITH THESE REQUIREMENTS, PLEASE CONTACT:**

- For Rules Interpretation, call (703) 308-1123
- For CRF submission help, call (703) 308-4212
- For PatentIn software help, call (703) 308-6856

APR 01 1999

  
Customer Service Center  
Initial Patent Examination Division (703) 308-1202

**PART 2 - COPY TO BE RETURNED WITH RESPONSE**



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

S. A. and H.B.  
5/14/99

Applicant(s): Boyle et al.

Serial No.: 09/211,297

Group Art Unit No.: 1652

Filed: December 14, 1998

Examiner: Not assigned

For: Osteoprotegerin Binding Proteins

Docket No.: A-451F

**ATTORNEY'S STATEMENT PURSUANT TO § 1.821(f)**

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

The computer readable form in this continuation application, is identical with that filed in application Serial No. 08/880,855, filed on June 23, 1997. In accordance with 37 CFR § 1.821(e), please use the only computer readable form filed in that application as the computer readable form for this application. It is understood that the Patent and Trademark Office will make the necessary change in the application number and filing date for the computer readable form that will be used for this application. A paper copy of the Sequence Listing is provided herewith. I hereby state that the paper copy and the computer readable form (CRF) of the "Sequence Listing" for the above-mentioned patent application are the same. Please charge any fees associated herewith to Deposit Account 01-0519 and consider this a petition therefore if appropriate.

The Applicants hereby request amendment of the specification as follows:

Please amend the page numbers as follows:

- Add new pages 51 through 68 after the specification
- Renumber remaining pages respectively

Pursuant to 37 CFR §1.821 (d), please amend the description as follows:

- At p. 8, line 8: after "SEQ ID NO:" insert - 37 -
- At p. 9, line 10: after "Figure 1 (SEQ ID NO:" insert - 36 -
- At p. 9, line 10: after "Figure 4 (SEQ ID NO:" insert - 38 -
- At p. 9, line 13: after "Figure 1 (SEQ ID NO:" insert - 36 -

RECEIVED

APR 6 1999

MATRIX CUSTOMER  
SERVICE CENTER

**CERTIFICATE OF MAILING**

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231, on the date appearing below.

March 22, 1999

Date

Clara Sorenson

Signature

Applicant: Boyle et al.  
USSN: 09/211,297  
Docket No. A-451F

At p. 9, line 13: after "Figure 4 (SEQ ID NO:" insert - 38 -  
At p. 9, line 32: after "Figure 1 (SEQ ID NO:" insert - 36 -  
At p. 9, line 33: after "Figure 4 (SEQ ID NO:" insert - 38 -  
At p. 10, line 12: after "Figure 1 (SEQ ID NO:" insert - 37 -  
At p. 10, line 13: after "Figure 4 (SEQ ID NO:" insert - 39 -  
At p. 11, line 2: after "Figure 1 (SEQ ID NO:" insert - 37 -  
At p. 11, line 5: after "Figure 4 (SEQ ID NO:" insert - 39 -  
At p. 11, line 13: after "Figure 1 (SEQ ID NO:" insert - 37 -  
At p. 11, line 19: after "Figure 4 (SEQ ID NO:" insert - 38 -  
At p. 33, line 17: after "COOH" insert - (SEQ ID NO: 1) -  
At p. 33, line 24: after "SEQ ID NO:" insert - 2 -  
At p. 33, line 27: after "SEQ ID NO:" insert - 3 -  
At p. 33, line 33: after "COOH" insert - (SEQ ID NO: 2) -  
At p. 34, line 6: after "SEQ ID NO:" insert - 5 -  
At p. 34, line 9: after "SEQ ID NO:" insert - 5 -  
At p. 34, line 15: after "COOH" insert - (SEQ ID NO: 7) -  
At p. 34, line 22: after "SEQ ID NO:" insert - 8 -  
At p. 34, line 25: after "SEQ ID NO:" insert - 6 -  
At p. 34, line 32: after "COOH" insert - (SEQ ID NO: 9) -  
At p. 35, line 4: after "SEQ ID NO:" insert - 10 -  
At p. 35, line 7: after "SEQ ID NO:" insert - 6 -  
At p. 35, line 13: after "COOH" insert - (SEQ ID NO: 11) -  
At p. 35, line 20: after "SEQ ID NO:" insert - 12 -  
At p. 35, line 23: after "SEQ ID NO:" insert - 6 -  
At p. 35, line 29: after "COOH" insert - (SEQ ID NO: 13) -  
At p. 36, line 4: after "SEQ ID NO:" insert - 14 -  
At p. 36, line 7: after "SEQ ID NO:" insert - 6 -  
At p. 36, line 14: after "COOH" insert - (SEQ ID NO: 15) -  
At p. 36, line 22: after "SEQ ID NO:" insert - 16 -  
At p. 36, line 25: after "SEQ ID NO:" insert - 3 -  
At p. 36, line 31: after "COOH" insert - (SEQ ID NO: 17) -  
At p. 37, line 4: after "SEQ ID NO:" insert - 18 -  
At p. 37, line 7: after "SEQ ID NO:" insert - 3 -  
At p. 37, line 13: after "COOH" insert - (SEQ ID NO: 19) -  
At p. 37, line 20: after "SEQ ID NO:" insert - 20 -  
At p. 37, line 23: after "SEQ ID NO:" insert - 3 -

Applicant: Boyle et al.  
USSN: 09/211,297  
Docket No. A-451F

- At p. 37, line 29: after "COOH" insert - (SEQ ID NO: 21) -  
At p. 38, line 4: after "SEQ ID NO:" insert - 22  
At p. 38, line 6: after "SEQ ID NO:" insert - 3 -  
At p. 38, line 12: after "COOH" insert - (SEQ ID NO: 3) -  
At p. 38, line 19: after "SEQ ID NO:" insert - 24 -  
At p. 38, line 21: after "SEQ ID NO:" insert - 3 -  
At p. 40, line 1: after "Phe-Ala-His" insert - (SEQ ID NO: 25) -  
At p. 44, line 10: after "CAG ATG" insert - (SEQ ID NO: 26) -  
At p. 44, line 12: after "CTT TG" insert - (SEQ ID NO: 27) -  
At p. 45, line 5: after "TTG C" insert - (SEQ ID NO: 28) -  
At p. 45, line 6: after "CTT TG" insert - (SEQ ID NO: 29) -  
At p. 45, line 19: after "CAT CA" insert - (SEQ ID NO: 30) -  
At p. 45, line 22: after "GTG GA" insert - (SEQ ID NO: 31) -  
At p. 47, line 17: after "COOH" insert - (SEQ ID NO: 32) -  
At p. 47, line 18: after "COOH" insert - (SEQ ID NO: 33) -  
At p. 47, line 19: after "COOH" insert - (SEQ ID NO: 34) -  
At p. 47, line 20: after "COOH" insert - (SEQ ID NO: 35) -  
At p. 52, line 7: after "Figure 1 (SEQ ID NO:" insert - 37 -  
At p. 52, line 7: after "Figure 4 (SEQ ID NO:" insert - 39 -  
At p. 52, line 10: after "Figure 1 (SEQ ID NO:" insert - 37 -  
At p. 52, line 10: after "Figure 4 (SEQ ID NO:" insert - 39 -  
At p. 52, line 30: after "SEQ ID NO:" insert - 36 -  
At p. 52, line 34: after "SEQ ID NO:" insert - 38 -  
At p. 53, line 6: after "SEQ ID NO:" insert - 38 -  
At p. 53, line 13: after "SEQ ID NO:" insert - 36 -  
At p. 53, line 14: after "SEQ ID NO:" insert - 38 -  
At p. 54, line 9: after "SEQ ID NO:" insert - 37 -  
At p. 54, line 10: after "SEQ ID NO:" insert - 39 -  
At p. 54, line 23: after "SEQ ID NO:" insert - 37 -  
At p. 54, line 28: after "SEQ ID NO:" insert - 39 -  
At p. 55, line 33: after "SEQ ID NO:" insert - 36 -  
At p. 55, line 34: after "SEQ ID NO:" insert - 38 -  
At FIGURE 1, line 3: before "GAGCTCGGAT..." insert -- (SEQ ID NO: 36) --


Claims  
1-36  
has  
been  
Cancelled

N.E.

Applicant: Boyle et al.  
USSN: 09/211,297  
Docket No. A-451F

*N.E.* At FIGURE 1, line 8: before "Met Arg Arg Ala Ser Arg. . ." insert -- (SEQ ID NO: 37) --  
At FIGURE 4, line 2: before "AAGCTTGGTAC. . ." insert -- (SEQ ID NO: 38) --  
At FIGURE 4, line 12: before "M R R A S . ." insert -- (SEQ ID NO: 39) --

Respectfully submitted,

  
Robert B. Winter  
Attorney/Agent for Applicant(s)  
Registration No.: 34,458  
Phone: (805) 447-2425  
Date: *MARCH 22, 1999*

Please send all future correspondence to:

U.S. Patent Operations/ RBW  
Dept. 430, M/S 27-4-A  
AMGEN INC.  
One Amgen Center Drive  
Thousand Oaks, California 91320-1789